For retail and specialty-lite pharmaceutical brands, the path from prescription to profit has never been more treacherous. While commercial teams focus on market access negotiations and formulary wins, a critical revenue leak often goes unnoticed: the gap between prior authorization (PA) requirements and submission rates, creating a cascade of gross-to-net (GTN) erosion that threatens long-term viability.